Table 1.
Characteristics of included studies.
| Study | Country | Study design | Sample size | Canakinumab | Control | Usage of canakinumab | Patients included | ||
|---|---|---|---|---|---|---|---|---|---|
| Agea | Male (%) | Agea | Male (%) | ||||||
| Caricchio4 2021 | Europe and America | RCT | 454 | 59 (49–69) | 135 (59%) | 57 (50–68) | 132 (58%) | Canakinumab 450 mg for body weight of 40-<60 kg, 600 mg for 60–80 kg, and 750 mg for>80 kg, intravenous | Patients hospitalized with severe COVID-19 without invasive mechanical ventilation |
| Cremer5 2021 | America | RCT | 45 | NR | 20 (68.96%) | 68.2 (56.1, 83.3) | 13 (81.3%) | Canakinumab 300 mg (n = 14), Canakinumab 600 mg (n = 15), intravenous | Hospitalized patients |
| Generali6 2021 | Italy | Prospective case-control study | 48 | 70 (29–89) | 25 (76%) | 69 (44–85) | 13 (87%) | canakinumab (150 mg) was administered by subcutaneous injection on day 1 and on day 7 | Hospitalized patients |
| Katia7 2021 | Italy | Retrospective cohort | 34 | 53 (48, 62) | 15 (88.2%) | 59 (50, 72) | 13 (76.5%) | A subcutaneous single dose of canakinumab 300 mg | Hospitalized mild or |
| severe non ICU patients | |||||||||
| Mastroianni8 2021 | Italy | Retrospective cohort | 20 | 56 (46–82) | 4 (50%) | NR | NR | 150 mg BID for a body weight of 60–80 kg (or 2 mg/kg for participants weighing ≤40 kg), subcutaneous | Hospitalized patients |
| Potalivo9 2020 | Italy | Retrospective cohort | 520 | NR | NR | NR | NR | NR | Hospitalized patients |
a
Age data presented as median (IQR) or mean (SD); ICU: intensive care units; RCT: randomized controlled trial; NR: not reported.